Building Better Payer Relationships in 2016: Three New Year’s Resolutions for Pharmaceutical Companies

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

It’s January, so right now it feels like everyone around us has made resolutions to get more exercise, eat better, or otherwise improve their lives. In that spirit, let’s take a look at what companies can do to improve their payer relationships in 2016. According to The Wall Street Journal, drug prices are on the rise, so the value propositions of health economics groups will be increasingly important when working with payers. Continue reading



Understanding the Potential Impact of Comparative Effectiveness Research in the US Payer Marketplace

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

The Institute for Clinical and Economic Review (ICER) announced in July that they are going to be producing reports on new drugs from a comparative effectiveness standpoint.  Quotes supporting ICER”s work from the Chief Medical Office of Express Scripts, Steve Miller MD, have raised questions within the industry about how the new influx of independent comparative effectiveness research will shape key decision-making processes on the payer side. Continue reading


Health Economics Spending: Prioritizing HEOR Activities at Global Groups

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Pharmaceutical companies under increasing pressure to provide a full product story to key payers.  As such, heath economics spending is also growing.  Rising stakeholder expectations demand that HEOR groups generate more pharmacoeconomic and outcomes data for each emerging drug or medical device.  To provide these data, global HEOR teams allocate a large percentage of their annual funding to cultivating  information for government and private payers worldwide. Continue reading


The Big Three: How Payers, Patients, and Physicians are Driving the Future of Comparative Effectiveness Research

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

Over the past few months at Cutting Edge Information we have been working on collecting data for a new report on comparative effectiveness research and a common theme throughout the research has been the need for stakeholder engagement that goes beyond the traditional payer-centric model.  Working with patients and physicians — along with pharmacies, regulators, and other stakeholders — is not a new phenomenon for manufacturers.  However, the emphasis on getting this engagement right is growing as companies respond to the changing healthcare marketplace in the US and in Europe. Continue reading





Majority of Global Health Economics and Outcomes Research Teams Begin Working with Developing Products in Phase 2

David Richardson, pharmaceutical commercialization and launch expert
By David Richardson,
Director of Research

In our most recent study examining health economics teams, 64% of responding global health economics and outcomes research teams revealed that they begin working with developing products during Phase 2 — though most desired an even earlier start.  HEOR directors and managers want early involvement to help them understand payers’ hot-button issues as early as possible. Continue reading


What Are Patients Saying? Using PRO Instruments to Impact Product Marketing Claims

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

As the pharmaceutical industry transitions to more patient-centric marketing, companies are looking to patient-reported outcomes to inform product labels.  Often, clinical or PRO teams will implement PRO instruments during Phase 2 or Phase 3 trials to collect end-user feedback.  This feedback is particularly useful as companies look to prove a product’s comparative effectiveness and product label claim approval.  While PRO endpoints are becoming increasingly popular, companies still find gaining approval for these findings is a complex process. Continue reading